Non-Stimulant ADHD Medications for Children
The three FDA-approved non-stimulant medications for ADHD in children are atomoxetine (Strattera), extended-release guanfacine (Intuniv), and extended-release clonidine (Kapvay), with atomoxetine being the first-line non-stimulant choice and alpha-2 agonists (guanfacine ER and clonidine ER) serving as alternatives or adjunctive therapy 1.
FDA-Approved Non-Stimulant Options
Atomoxetine (Strattera)
- Mechanism: Selective norepinephrine reuptake inhibitor
- Target dose: 1.2 mg/kg/day, given once or twice daily 1
- Onset: Effects build over several weeks; not immediate like stimulants
- Advantages: 24-hour symptom coverage, no abuse potential, effective for comorbid anxiety/tics 2
Key monitoring requirements for atomoxetine:
- Obtain personal and family cardiac history before initiation
- Monitor heart rate and blood pressure (can increase both) 1
- Perform ECG if cardiac risk factors present 1
- Watch for suicidal ideation (FDA black box warning) 1
- Monitor liver function (extremely rare hepatitis risk) 1
- Track growth parameters (temporary delays in first 1-2 years, normalizes by 2-3 years) 1
Common side effects: Initial somnolence, gastrointestinal symptoms (especially with rapid titration), decreased appetite 1
Extended-Release Guanfacine (Intuniv)
- Mechanism: Alpha-2A adrenergic agonist
- Use: Monotherapy or adjunctive with stimulants (FDA-approved for both) 1
Key monitoring requirements:
- Obtain cardiac history and perform ECG if risk factors present 1
- Monitor heart rate and blood pressure (both decrease) 1
- Critical: Must taper when discontinuing—never stop abruptly due to rebound hypertension risk 1
Common side effects: Somnolence, dry mouth, dizziness, irritability, headache, bradycardia, hypotension, abdominal pain 1
Extended-Release Clonidine (Kapvay)
- Mechanism: Alpha-2 adrenergic agonist
- Use: Monotherapy or adjunctive with stimulants (FDA-approved for both) 1
Monitoring and precautions: Same as guanfacine ER above, including mandatory tapering to avoid rebound hypertension 1
Clinical Decision Algorithm
When to use non-stimulants as first-line:
- Stimulant side effects are intolerable
- Inadequate response to stimulants
- Risk of stimulant diversion/abuse concerns
- Family preference to avoid stimulants
- Comorbid tic disorders (atomoxetine preferred)
- Comorbid anxiety disorders (atomoxetine may help)
- Need for 24-hour symptom coverage without rebound 3, 2
When to use as adjunctive therapy:
- Stimulants provide partial but insufficient response
- Only guanfacine ER and clonidine ER have FDA approval for adjunctive use 1
- Atomoxetine can be combined with stimulants off-label with limited supporting evidence 1
Special Population: Preschool Children (Ages 4-5)
No non-stimulant medication has sufficient evidence for use in preschool-aged children with ADHD 1. Methylphenidate is the recommended medication for this age group when pharmacotherapy is needed, though this remains off-label use.
Important Caveats
Cardiovascular screening is mandatory before starting any non-stimulant:
- Personal history of cardiac symptoms
- Family history of sudden death, Wolff-Parkinson-White syndrome, hypertrophic cardiomyopathy, long QT syndrome
- If any risk factors present: obtain ECG and consider cardiology referral 1
The risk of serious cardiovascular events is extremely low with non-stimulants, similar to stimulants, but the directional effects differ: atomoxetine increases HR/BP while guanfacine and clonidine decrease HR/BP 1.
Never abruptly discontinue alpha-2 agonists (guanfacine ER, clonidine ER)—always taper to prevent rebound hypertension 1.
Atomoxetine requires specific monitoring for suicidal ideation, particularly when initiating or adjusting doses, due to FDA black box warning 1.
Newer Option
Viloxazine extended-release is a newer FDA-approved norepinephrine reuptake inhibitor that provides an additional non-stimulant option, though it was not extensively covered in the primary guidelines reviewed 3, 2.